In a Federal Register Notice of August 27, 2021, the Office of the U.S. Trade Representative (“USTR”) announced that it is seeking comments on the extension of existing China 301 exclusions on certain medical care products.

On December 29, 2020, in response to the evolving COVID-19 situation, the USTR had announced that it was extending certain expiring China 301 tariff exclusions on medical care products and designating certain additional such exclusions for the period January 1, 2021 through March 31, 2021.  Such exclusions (99 in total) were extended through September 30, 2021.

In light of various factors, including the rise in COVID-19 cases in the U.S. and the ability to obtain certain products from domestic and foreign sources, the USTR is requesting public comments on whether to extend the medical care product exclusions for up to six months.  The list of the particular products in question can be found at: https://www.gdlsk.com/ustr-extends-certain-china-301-exclusions-and-designates-additional-exclusions-for-the-period-january-1-march-31-2021/?highlight=medical%20care%20products.

Comments are being accepted through September 27, 2021.

We are available to assist with the preparation of comments and to otherwise discuss China 301 mitigation strategies.

Please do not hesitate to contact Arthur Bodek or any of our attorneys for further information.